MX2007015848A - Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2. - Google Patents

Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2.

Info

Publication number
MX2007015848A
MX2007015848A MX2007015848A MX2007015848A MX2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A
Authority
MX
Mexico
Prior art keywords
type
risk
diabetes mellitus
genetic variants
diagnostic markers
Prior art date
Application number
MX2007015848A
Other languages
English (en)
Spanish (es)
Inventor
Struan F A Grant
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of MX2007015848A publication Critical patent/MX2007015848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2007015848A 2005-06-20 2006-06-16 Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2. MX2007015848A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69217405P 2005-06-20 2005-06-20
US75715506P 2006-01-06 2006-01-06
PCT/IS2006/000014 WO2006137085A1 (en) 2005-06-20 2006-06-16 Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2007015848A true MX2007015848A (es) 2008-04-22

Family

ID=37036993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015848A MX2007015848A (es) 2005-06-20 2006-06-16 Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2.

Country Status (14)

Country Link
US (3) US7585630B2 (enExample)
EP (1) EP1907569B1 (enExample)
JP (1) JP5301987B2 (enExample)
KR (1) KR101374304B1 (enExample)
CN (1) CN101238222B (enExample)
AU (1) AU2006260477B2 (enExample)
BR (1) BRPI0612301A2 (enExample)
CA (1) CA2612475C (enExample)
EA (1) EA016397B1 (enExample)
IL (1) IL188147A (enExample)
MX (1) MX2007015848A (enExample)
NO (1) NO341910B1 (enExample)
NZ (1) NZ564285A (enExample)
WO (1) WO2006137085A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR101374304B1 (ko) * 2005-06-20 2014-03-14 디코드 제네틱스 이에이치에프 타입 2 당뇨병의 위험에 대한 진단 마커인 ｔｃｆ7ｌ2유전자의 유전적 변이체
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US20100086921A1 (en) * 2006-11-30 2010-04-08 Valgerdur Steinthorsdottir Genetic susceptibility variants of type 2 diabetes mellitus
EP2057183A2 (en) * 2007-03-01 2009-05-13 Novetide Ltd. High purity peptides
EP2155903A4 (en) * 2007-04-30 2010-12-01 Compugen Ltd ALLELIC POLYMORPHISM ASSOCIATED WITH DIABETES
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US8796182B2 (en) 2009-07-10 2014-08-05 Decode Genetics Ehf. Genetic markers associated with risk of diabetes mellitus
KR20120107080A (ko) * 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2971163A4 (en) * 2013-03-14 2017-03-22 The Children's Hospital of Philadelphia Tcf7l2 variant and methods of use thereof in diagnostic and drug screening assays
RU2521202C1 (ru) * 2013-04-12 2014-06-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Способ прогнозирования риска развития сахарного диабета второго типа у больных гипертонической болезнью
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN103882127B (zh) * 2014-03-13 2016-03-16 河北联合大学 用于预测患2型糖尿病肾病发生风险的试剂盒
WO2016201438A1 (en) * 2015-06-11 2016-12-15 The Children's Hospital Of Philadelphia New targets modulated by a casual variant of type 2 diabetes (t2d) embedded within the tcf7l2 gene and methods of use thereof for identifying agents having efficacy for the treatment of type 2 diabetes and other metabolic disorders
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
CN109182508A (zh) * 2018-10-22 2019-01-11 北京华夏时代生物工程有限公司 Tcf7l2基因单核苷酸多态性的荧光原位杂交测序方法
TWI702292B (zh) * 2018-12-28 2020-08-21 薩摩亞商康多富國際有限公司 個人化新陳代謝疾病保健食品組合的決定方法及非暫態電腦可讀取儲存媒體

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5288611A (en) * 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
JPS60501339A (ja) * 1983-01-10 1985-08-22 ジエン−プロ−ブ　インコ−ポレィテッド 生物を検出、同定又は定量する方法およびキット
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3534934A1 (de) * 1985-10-01 1987-04-02 Draegerwerk Ag Kolorimetrisches gasdosimeter
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
US6153618A (en) 1996-10-11 2000-11-28 Chiron Corporation Inhibitors of glycogen synthase 3 kinase
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
KR100688308B1 (ko) 1999-12-17 2007-02-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 글리코겐 신타아제 키나제3의 피라진 기제 저해제
WO2001044246A1 (en) 1999-12-17 2001-06-21 Chiron Corporation Bicyclic inhibitors of glycogen synthase kinase 3
JP2004504838A (ja) 2000-07-27 2004-02-19 カイロン　コーポレイション Ｇｓｋ３ポリペプチド
AU785425B2 (en) * 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
JP2004536113A (ja) 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
US20030170665A1 (en) * 2001-08-04 2003-09-11 Whitehead Institute For Biomedical Research Haplotype map of the human genome and uses therefor
WO2003024447A1 (en) 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
US20040072831A1 (en) 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
EP1549144A4 (en) 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
JP2006506988A (ja) * 2002-11-01 2006-03-02 デコード ジェネティクス イーエッチエフ． 染色体５ｑ３５に位置したヒトＩＩ型糖尿病遺伝子−ＳＬＩＴ−３
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits
CN1548553A (zh) * 2003-05-21 2004-11-24 中国医学科学院基础医学研究所 用于预测2型糖尿病易感性的试剂盒及引物
US6991110B2 (en) * 2003-07-02 2006-01-31 Inficon, Inc. Package for storing sensor crystals and related method of use
KR20060121842A (ko) 2003-08-28 2006-11-29 주식회사 중외제약 β-카테닌/ＴＣＦ에 의해 활성화되는 전사의 조절
KR101374304B1 (ko) * 2005-06-20 2014-03-14 디코드 제네틱스 이에이치에프 타입 2 당뇨병의 위험에 대한 진단 마커인 ｔｃｆ7ｌ2유전자의 유전적 변이체

Also Published As

Publication number Publication date
KR101374304B1 (ko) 2014-03-14
HK1117569A1 (en) 2009-01-16
AU2006260477A8 (en) 2006-12-28
NO20080389L (no) 2008-01-21
CN101238222B (zh) 2013-04-10
EP1907569A1 (en) 2008-04-09
EA200800087A1 (ru) 2008-06-30
AU2006260477B2 (en) 2012-02-23
KR20080051128A (ko) 2008-06-10
CN101238222A (zh) 2008-08-06
US20120149016A1 (en) 2012-06-14
JP5301987B2 (ja) 2013-09-25
US7585630B2 (en) 2009-09-08
NZ564285A (en) 2010-03-26
EP1907569B1 (en) 2013-04-10
JP2008546403A (ja) 2008-12-25
BRPI0612301A2 (pt) 2009-01-27
EA016397B1 (ru) 2012-04-30
AU2006260477A1 (en) 2006-12-28
US20090275043A1 (en) 2009-11-05
NO341910B1 (no) 2018-02-19
IL188147A (en) 2013-02-28
CA2612475A1 (en) 2006-12-28
WO2006137085A1 (en) 2006-12-28
US20060286588A1 (en) 2006-12-21
CA2612475C (en) 2015-07-28
IL188147A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
MX2007015848A (es) Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2.
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
IL225203A (en) An isolated complementary factor polypeptide, methods for its preparation, its uses and a factor that lowers its expression or activity
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
IL249715B (en) N-butyl-deoxynojirimycin for use as a drug for the treatment of Pompe disease in combination with an enzyme replacement therapy agent
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2008103470A3 (en) Oncogenic-ras-signal dependent lethal compounds
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
ATE528300T1 (de) Bizyklische verbindungen und ihre verwendung als antidiabetika
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2011001135A3 (en) Diagnosis and treatment of alzheimer's disease
WO2009059318A3 (en) Genes and polymorphisms associated with amd
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2007149798A3 (en) Biomarkers for the progression of alzheimer's disease
WO2007095185A3 (en) Variants in complement regulatory genes predict age-related macular degeneration
WO2009036100A8 (en) Prediction of qt prolongation based on snp genotype
WO2008065682A3 (en) Genetic susceptibility variants of type 2 diabetes mellitus
PL1730315T3 (pl) Polimorfizmy w genie NOD2/CARD15
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
WO2010008858A8 (en) Use of iron-related pathways and genes for treatment and diagnosis of parkinson's disease
WO2008081447A3 (en) Compounds and methods for detection of cells
WO2010011626A3 (en) Pyridinyl modulators of ϒ-secretase
WO2006063703A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2007063405A3 (en) Diagnosis and treatment of exocrine pancreatic dysfunction and diabetes using human cel gene

Legal Events

Date Code Title Description
FG Grant or registration